News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
731,209 Results
Type
Article (41626)
Company Profile (265)
Press Release (689302)
Multimedia
Podcasts (93)
Webinars (20)
Section
Business (204981)
Career Advice (2045)
Deals (35609)
Drug Delivery (128)
Drug Development (81635)
Employer Resources (174)
FDA (16543)
Job Trends (15006)
News (347143)
Policy (32806)
Tag
2027 BioCapital Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Standard (3)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (5)
Academia (2599)
Accelerated approval (47)
Adcomms (26)
Allergies (172)
Alliances (49620)
ALS (210)
Alzheimer's disease (1803)
Antibody-drug conjugate (ADC) (446)
Approvals (16919)
Artificial intelligence (658)
Autoimmune disease (292)
Automation (56)
Bankruptcy (362)
Best Places to Work (11644)
BIOSECURE Act (20)
Biosimilars (221)
Biotechnology (175)
Bladder cancer (188)
Brain cancer (71)
Breast cancer (747)
Cancer (5800)
Cardiovascular disease (468)
Career advice (1734)
Career pathing (42)
CAR-T (331)
CDC (56)
Celiac Disease (3)
Cell therapy (899)
Cervical cancer (47)
Clinical research (70881)
Collaboration (2050)
Company closure (5)
Compensation (1389)
Complete response letters (80)
COVID-19 (2744)
CRISPR (107)
C-suite (1118)
Cystic fibrosis (152)
Data (7853)
Decentralized trials (3)
Denatured (27)
Depression (161)
Dermatology (86)
Diabetes (586)
Diagnostics (6929)
Digital health (54)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (317)
Drug pricing (201)
Drug shortages (31)
Duchenne muscular dystrophy (284)
Earnings (92094)
Editorial (66)
Employer branding (22)
Employer resources (153)
Events (119507)
Executive appointments (1079)
FDA (20252)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (16)
Frontotemporal dementia (34)
Funding (1717)
Gene editing (233)
Generative AI (56)
Gene therapy (721)
GLP-1 (1054)
Government (4739)
Grass and pollen (6)
Guidances (408)
Healthcare (18997)
HIV (79)
Huntington's disease (56)
IgA nephropathy (97)
Immunology and inflammation (291)
Immuno-oncology (92)
Indications (191)
Infectious disease (3081)
Inflammatory bowel disease (216)
Inflation Reduction Act (14)
Influenza (136)
Intellectual property (288)
Interviews (324)
IPO (16675)
IRA (50)
Job creations (3663)
Job search strategy (1438)
JPM (59)
Kidney cancer (19)
Labor market (100)
Layoffs (567)
Leadership (39)
Legal (7975)
Liver cancer (101)
Longevity (32)
Lung cancer (762)
Lymphoma (431)
Machine learning (60)
Management (59)
Manufacturing (1043)
MASH (186)
Medical device (13927)
Medtech (14048)
Mergers & acquisitions (20174)
Metabolic disorders (1496)
mRNA (207)
Multiple sclerosis (188)
NASH (17)
Neurodegenerative disease (417)
Neuropsychiatric disorders (106)
Neuroscience (3307)
Neurotech (1)
NextGen: Class of 2026 (6529)
Non-profit (4533)
Now hiring (78)
Obesity (699)
Opinion (292)
Ovarian cancer (220)
Pain (252)
Pancreatic cancer (299)
Parkinson's disease (359)
Partnered (33)
Patents (592)
Patient recruitment (667)
Peanut (63)
People (59631)
Pharmaceutical (59)
Pharmacy benefit managers (32)
Phase 1 (22083)
Phase 2 (31223)
Phase 3 (23260)
Pipeline (8692)
Policy (316)
Postmarket research (2573)
Preclinical (9410)
Press Release (64)
Prostate cancer (299)
Psychedelics (54)
Radiopharmaceuticals (320)
Rare diseases (1074)
Real estate (5977)
Recruiting (71)
Regulatory (25412)
Reports (56)
Research institute (2417)
Resumes & cover letters (354)
Rett syndrome (39)
RNA editing (21)
RSV (88)
Schizophrenia (176)
Series A (288)
Series B (213)
Service/supplier (11)
Sickle cell disease (112)
Special edition (23)
Spinal muscular atrophy (168)
Sponsored (48)
Startups (3645)
State (2)
Stomach cancer (18)
Supply chain (126)
Tariffs (87)
The Weekly (64)
Vaccines (1091)
Venture capital (108)
Weight loss (451)
Women's health (125)
Worklife (20)
Date
Today (123)
Last 7 days (852)
Last 30 days (3576)
Last 365 days (30183)
2026 (12410)
2025 (30191)
2024 (35230)
2023 (40087)
2022 (51198)
2021 (55729)
2020 (54097)
2019 (46576)
2018 (35049)
2017 (32149)
2016 (31508)
2015 (37567)
2014 (31334)
2013 (26378)
2012 (28602)
2011 (29309)
2010 (27345)
Location
Africa (746)
Alabama (93)
Alaska (7)
Arizona (348)
Arkansas (14)
Asia (39704)
Australia (6521)
California (13247)
Canada (3763)
China (1334)
Colorado (566)
Connecticut (577)
Delaware (403)
Europe (85932)
Florida (1981)
Georgia (425)
Hawaii (3)
Idaho (62)
Illinois (1051)
India (90)
Indiana (600)
Iowa (23)
Japan (535)
Kansas (131)
Kentucky (50)
Louisiana (40)
Maine (76)
Maryland (1586)
Massachusetts (9441)
Michigan (362)
Minnesota (715)
Mississippi (6)
Missouri (144)
Montana (33)
Nebraska (29)
Nevada (142)
New Hampshire (84)
New Jersey (3481)
New Mexico (29)
New York (3462)
North Carolina (1678)
North Dakota (9)
Northern California (6643)
Ohio (396)
Oklahoma (23)
Oregon (41)
Pennsylvania (2665)
Puerto Rico (29)
Rhode Island (50)
South America (1115)
South Carolina (85)
South Dakota (2)
Southern California (5222)
Tennessee (210)
Texas (2104)
United States (46705)
Utah (393)
Vermont (1)
Virginia (321)
Washington D.C. (80)
Washington State (1060)
West Virginia (4)
Wisconsin (125)
Wyoming (2)
731,209 Results for "genentech inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
FDA Accepts Application for Genentech’s Gazyva for the Treatment of the Most Common Form of Lupus
April 21, 2026
·
14 min read
Layoffs
Genentech’s Latest Layoffs Bring Total to Nearly 350 This Year
Genentech is letting go of 118 employees in South San Francisco. The news comes about two months after the biotech ended a partnership with Adaptive Biotechnologies.
October 29, 2025
·
1 min read
·
Angela Gabriel
Press Releases
CORRECTING and REPLACING FDA Accepts Application for Genentech’s Gazyva for the Treatment of the Most Common Form of Lupus
April 21, 2026
·
15 min read
Press Releases
Genentech’s Enspryng (Satralizumab) Reduces Risk of Relapses by 68% Demonstrating Potential to Become First Treatment for MOGAD
April 22, 2026
·
12 min read
Press Releases
Genentech’s Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS
April 22, 2026
·
15 min read
Press Releases
Genentech to Present Extensive Data Showcasing Its Industry-Leading Ophthalmology Portfolio at ARVO 2026
April 30, 2026
·
15 min read
Press Releases
FDA Approves Genentech’s Venclexta® Plus Acalabrutinib Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia
February 20, 2026
·
17 min read
Press Releases
FDA Accepts New Drug Application for Genentech’s Giredestrant in ESR1-Mutated, ER-Positive Advanced Breast Cancer
February 20, 2026
·
8 min read
Immuno-oncology
Genentech Walks Away From $2B Partnership With Adaptive Biotechnologies
Adaptive and Genentech first partnered in 2018 to advance T cell receptor-based therapies for cancer.
August 19, 2025
·
1 min read
·
Tristan Manalac
Press Releases
New England Journal of Medicine Publishes Phase III ALLEGORY Data Showing Genentech’s Gazyva Significantly Reduces Disease Activity in the Most Common Form of Lupus
March 9, 2026
·
16 min read
1 of 73,121
Next
